





GERIATRIC ASSESSMENT NOW AND THEN


Lodovico Balducci M.D. Moffitt Cancer Center Tampa, FL, USA























GOALS OF TREATMENT


- Increased survival
- Increased active life expectancy
- Symptom management
- Preservation of existential meaning

New symptoms

- Fatigue
- Cognitive Decline
- Functional impairments
- Existential suffering

Causes of fatigue

- Cytokines
- Hypogonadism
- Anemia
- Depression
- Deconditioning
- Sarcopenia



Existential suffering

- An euphemism for desperation?
- Terminal sedation: an euphemism for euthanasia?

What has changed since?

• The definition of frailty

The definition of frailty

Frailty = end of life


- > 85
- Dependence in one or more ADLs and/or one or more geriatric syndromes
- Three or more comorbidities

Frailty = risk to lose independent living

- Loss of <u>></u> 10 lbs in one year
- Decreased grip strength
- · Decreased walk speed
- Decreased energy level
- Decreased ability to initiate a movement


New questions

- Do cancer and its treatment unmask frailty
- Do cancer and its treatment cause frailty?



Comorbidity

- Reduced survival
- Reduced tolerance of treatment
- Comorbidity and cancer growth
- Comorbidity and polypharmacy



	ined Analysis Under I	Cominant Model				
SNP	Genotype	No. of Cases/ No. of Controls	Crude OR (95% CI)	P Value	Adjusted OR (95% CI) ^a	P Valu
JNF	Genotype	NO. OF CONTROLS	ADIPOQ	value	(80.)0 00	V di U
rs266729	CC	321/443	1 [Reference]		1 [Reference]	
	GG/CG	308/412	0.64 (0.49-0.83)	.001	0.73 (0.53-0.99)	.04
rs822395	CC	230/287	1 [Reference]		1 [Reference]	
	AA/AC	394/563	0.90 (0.72-1.11)	.32	0.79 (0.61-1.02)	.07
rs822396	GG	120/166	1 [Reference]		1 [Reference]	
	AA/GA	505/677	1.04 (0.80-1.35)	.77	1.11 (0.81-1.52)	.51
rs2241766	TT	292/336	1 [Reference]		1 [Reference]	
	GG/TG	347/507	0.77 (0.62-0.94)	.01	0.83 (0.66-1.05)	.12
rs1501299	TT	195/310	1 [Reference]		1 [Reference]	
	GG/TG	436/522	1.29 (1.04-1.61)	.02	1.16 (0.91-1.48)	.24
			ADIPOR1			
rs2232853	GG	255/338	1 [Reference]		1 [Reference]	
	AA/GA	364/508	0.98 (0.80-1.21)	.86	0.94 (0.74-1.17)	.56
rs12733285	TT	240/361	1 [Reference]		1 [Reference]	
	CC/TC	392/483	1.21 (0.98-1.49)	.07	1.16 (0.91-1.48)	.23
rs1342387	TT	131/211	1 [Reference]		1 [Reference]	
	CC/TC	494/628	1.02 (0.82-1.25)	.89	0.88 (0.67-1.15)	.35
rs7539542	GG	235/304	1 [Reference]		1 [Reference]	
	CC/GC	394/539	0.95 (0.76-1.17)	.61	0.94 (0.73-1.20)	.61
rs10920531	CC	293/374	1 [Reference]		1 [Reference]	
	AA/CA	330/468	0.92 (0.75-1.12)	.40	0.93 (0.73-1.18)	.54





Comorbidity, its treatment and cancer


- Epo and cancer of the head and neck
- · Epo and breast cancer
- Insulin and stimulation of cancer growth (ILGFR)


What has changed since?


New insights into aging




















Problems of the caregiver

- Diseases
- · Family dissolution
- Cost

Social implications of aging

Increased prevalence of chronic diseases + Increased prevalence of disability = Increased \$

Direct cost Indirect cost medical related Indirect cost non medical related Intangible cost

Social implications of aging: response to increased cost

- Shifting of cost from entertainment to medical care
- Cut unnecessary cost (increased use of living will, elimination of "me too" drugs, elimination of unnecessary diagnostic tests, reduce regulatory burden, change the process of drugs approval)
- Rationing
- Discrimination

Ethic implications of aging

Kantian ethics:

- Rationing yes
- Discrimination no

Utilitarian ethics:

Discrimination based on economic power

